Yazarlar : Pennell D, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A.
Yayın : Haematologica.
Yayın Yılı : 2012
Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22271905
Konu : Talasemi
Literatür İçeriği :
Abstract
Background. Prospective data on cardiac iron removal are limited beyond 1 year, hence longer-term studies are important.Design and methods. Seventy-one patients in the EPIC cardiac substudy elected to continue into the third year, enabling analysis of cardiac iron removal over 3 years.Results. Mean deferasirox dose during year 3 was 33.6+/-9.8mg/kg per day. Myocardial T2*, assessed by cardiovascular magnetic resonance, significantly increased from 12.0+/-39.1% at baseline to 17.1+/-62.0% at end of study (P<0.001), corresponding to a decrease in cardiac iron concentration (based on ad-hoc analysis of T2*) from 2.43±1.2mg Fe/g dry weight (dw) at baseline to 1.80+/-1.4mg Fe/g dw at end of study (P<0.001). After 3 years, 68.1% of patients with baseline T2* 10 to <20 ms normalized (≥20ms) and 50.0% of patients with baseline T2* >5 to <10ms improved to 10 to <20ms. Left ventricular ejection fraction did not vary significantly throughout. No deaths occurred and the most common investigator-assessed drug-related adverse event in year 3 was increased serum creatinine (n=9, 12.7%).Conclusions. Three years of deferasirox treatment along with a clinically manageable safety profile significantly reduced cardiac iron overload versus baseline and normalized T2* in 68.1% (32/47) of patients with T2* 10 to <20ms.
| Sunumlar | Videolar | Olgu Tartışması |
